Targeting the peptidase PCSK9 to reduce cardiovascular risk: Implications for basic science and upcoming challenges

LDL cholesterol (LDL‐C) plays a central role in the progression of atherosclerosis. Statin therapy for lowering LDL‐C reduces the risk of atherosclerotic cardiovascular disease and is the recommended first‐line treatment for patients with high LDL‐C levels. However, some patients are unable to achieve an adequate reduction in LDL‐C with statins or are statin‐intolerant; thus, PCSK9 inhibitors were developed to reduce LDL‐C levels, instead of...